26-Nov-2024 3:15 PM CST - Business Wire Summit Therapeutics to Present at Upcoming Investor Conferences $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (Summit, we, or the Company) today announced that it will participate in and present at the 7th Annual Evercore HealthCONx Conference and Citis 2024 Global Healthcare Conference, both being held in Miami. Our management team will participate in fireside chats surrounding the development of our innovative investigational bispecific antibody, ivonescimab, at the Evercore HealthCONx Conference on Tuesday December 3, 2024 at 8:4
30-Oct-2024 6:00 AM CST - Business Wire Summit Therapeutics Reports Operational Progress and Financial Results for the Third Quarter and Nine Months Ended September 30, 2024 $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reported an update on its operational progress and financial results for the third quarter and nine months ended September 30, 2024. Operational & Corporate Updates Our operational progress continues with ivonescimab (SMT112), an investigational, potentially first-in-class bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects
23-Oct-2024 3:15 PM CST - Business Wire Summit Therapeutics to Host Third Quarter 2024 Financial Results & Operational Progress Call on October 30, 2024 $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (Summit, we, or the Company) will host an earnings call to announce its third quarter 2024 financial results and provide an operational update for the Company on Wednesday, October 30, 2024, before the market opens. Summit will host a live webcast of the earnings conference call at 9:00am ET, which will be accessible through our website, www.smmttx.com. An archived edition of the session will be available on our website. Abou
26-Nov-2024 3:15 PM CST - Business Wire Summit Therapeutics to Present at Upcoming Investor Conferences $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (Summit, we, or the Company) today announced that it will participate in and present at the 7th Annual Evercore HealthCONx Conference and Citis 2024 Global Healthcare Conference, both being held in Miami. Our management team will participate in fireside chats surrounding the development of our innovative investigational bispecific antibody, ivonescimab, at the Evercore HealthCONx Conference on Tuesday December 3, 2024 at 8:4
30-Oct-2024 6:00 AM CST - Business Wire Summit Therapeutics Reports Operational Progress and Financial Results for the Third Quarter and Nine Months Ended September 30, 2024 $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reported an update on its operational progress and financial results for the third quarter and nine months ended September 30, 2024. Operational & Corporate Updates Our operational progress continues with ivonescimab (SMT112), an investigational, potentially first-in-class bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects
23-Oct-2024 3:15 PM CST - Business Wire Summit Therapeutics to Host Third Quarter 2024 Financial Results & Operational Progress Call on October 30, 2024 $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (Summit, we, or the Company) will host an earnings call to announce its third quarter 2024 financial results and provide an operational update for the Company on Wednesday, October 30, 2024, before the market opens. Summit will host a live webcast of the earnings conference call at 9:00am ET, which will be accessible through our website, www.smmttx.com. An archived edition of the session will be available on our website. Abou
